Exhibit 99.1 Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026 EB612, the first long-acting oral PTH peptide replacement tablet for patients with hypoparathyroidism - final variants selected, pre- IND initiatives underway with intention to file IND ...